免费获得国外相关药品，最快 1 个工作日回馈药物信息
The Anti-oxidant Effects of N-Acetylcysteine in Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a condition defined as a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of lungs to noxious particles or gases, primarily caused by cigarette smoking. The accelerated decline in lung function is closely associated with an increased number of neutrophils in the sputum and hence with higher level of airway inflammation. It becomes clear that the inflammatory process potentiates as COPD progresses and exerts damage which is irreversible. Oxidative stress is inextricably linked to the inflammatory response.
There is increasing evidence that an oxidant/antioxidant imbalance, in favor of oxidants, occurs in COPD.
NAC has been reported to reduce the viscosity of sputum in both cystic fibrosis and COPD, facilitating the removal of pulmonary secretions. Moreover, by maintaining the airway clearance, it prevents bacterial stimulation of mucin production and hence mucus hypersecretion.
The superiority of NAC over the other mucolytics may be in its anti-inflammatory and antioxidant properties and its mucolytic actions.
The aim of this study is to evaluate the effects of treatment with NAC long on oxidative stress marker change and also explore the effect of NAC to airway inflammatory, lung function test and CAT scores. Selected oxidative stress marker was defined as 8 - isoprostane, protein carbonyl, DNA damage.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Obstructive Pulmonary Disease | Drug: N-acetylcysteine | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 30 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | Pre-post study |
| Masking: | None (Open Label) |
| Primary Purpose: | Basic Science |
| Official Title: | The Effects of N-Acetylcysteine on Oxidative Stress Markers in Chronic Obstructive Pulmonary Disease (COPD) |
| Estimated Study Start Date : | June 1, 2019 |
| Estimated Primary Completion Date : | January 5, 2020 |
| Estimated Study Completion Date : | May 1, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: N-acetylcysteine treatment
All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
|
Drug: N-acetylcysteine
All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
|
- Level of 8 - isoprostane, MDA and DNA damage in sputum [ Time Frame: 4 weeks ]
To measure the different level of 8 - isoprostane, MDA and DNA damage in sputum before and after treated with NAC long in patients in this study, Reduce from first measurement.
The level of 8 - isoprostane, MDA and DNA damage are reported according to ELISA based on the manufacturer's instructions.
- Percentage of Neutrophil in sputum [ Time Frame: 4 weeks ]
To measure the number of Neutrophil in sputum before and after treated with NAC long in patients in this study, Reduce from first measurement.
Total cell counts are recorded with on a hemocytometer, using Kimura staining. Cell viability is determined by Trypan blue exclusion before cytospins were undertaken. The slides are stained with May-Grunwald-Giemsa stain and differential cell counts were made by a blinded observer. Four hundred inflammatory cells are counted on two slides for each sample in a blinded manner. Differential cell counts are expressed as the percentages of total Neutrophil will be reported.
Samples with cell viability of greater than 70% and less than 30% squamous cell contamination are considered adequate for analysis.
- FVC [ Time Frame: 4 weeks ]To measure the FVC with Spirometry before and after treated with NAC long in patients in this study, improve from first measurement in FVC will be reported.
- FEV1 [ Time Frame: 4 weeks ]To measure the FEV1 with Spirometry before and after treated with NAC long in patients in this study, improve from first measurement in FEV1 will be reported.
- FEV1/FVC [ Time Frame: 4 weeks ]To measure the FEV1/FVC with Spirometry before and after treated with NAC long in patients in this study, improve from first measurement in FEV1/FVC will be reported.
- COPD Assessment Test (CAT TM) [ Time Frame: 4 weeks ]
To measure the COPD Assessment Test (CATTM) before and after treated with NAC long in patients in this study.
CATTM is Patient-completed questionnaire assessing globally the impact of COPD (cough, sputum, dyspnea, chest tightness) on health status of COPD patient.
The minimum score is Zero (0) and the maximum score is Forty (40). Please see the correlation of score and impact level as in below table.
CAT score
Impact level
>30 = Very high
>20 = High
10-20 = Medium
<10 = Low
5 = -
In each question, there are score from 0 to five, the higher values represent the worse current situation. Score from each question will be summed then interpret based on CATTM Healthcare Professional User Guide ,Reduce test score from first measurement will be reported.
| Ages Eligible for Study: | 40 Years to 90 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Eligible stable COPD patients who are currently treated with only short-acting bronchodilator (salbutamol or fenoterol/ipratropium bromide) or long-acting bronchodilator (LABA or LAMA) or inhaled corticosteroids/LABA
- Pre-bronchodilator FEV1 ≥ 80% and < 80% predicted
- Current or ex-smokers (≥ 10 pack year)
Exclusion Criteria:
- Concomitant with active and old pulmonary TB, lung cancer, bronchiectasis, lung fibrosis, destroyed lung and other malignancies
- Recent acute coronary syndrome (within 12 weeks)
- Cerebrovascular disease without neurological recovery
- Cognitive impairment
- Recent acute exacerbation of COPD (within 4 weeks)
- Recent respiratory viral infection (within 4 weeks)
- Could not provide adequate sputum specimens
- Develop worsening of COPD symptoms during sputum induction
- Could not provide informed consent
| Contact: Kittipong Maneechotesuwan, MD., PhD. | 6624197757 ext 15 | kittipong.man@mahidol.ac.th |
| Thailand | |
| Faculty of Medicine, Siriraj Hospital, Mahidol University | |
| Bangkok, Thailand, 10700 | |
| Principal Investigator: | Kittipong Maneechotesuwan, MD., PhD. | Faculty of Medicine Siriraj Hospital |
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Submitted Date ICMJE | June 7, 2018 | ||||
| First Posted Date ICMJE | May 21, 2019 | ||||
| Last Update Posted Date | May 21, 2019 | ||||
| Estimated Study Start Date ICMJE | June 1, 2019 | ||||
| Estimated Primary Completion Date | January 5, 2020 (Final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE |
Level of 8 - isoprostane, MDA and DNA damage in sputum [ Time Frame: 4 weeks ] To measure the different level of 8 - isoprostane, MDA and DNA damage in sputum before and after treated with NAC long in patients in this study, Reduce from first measurement.
The level of 8 - isoprostane, MDA and DNA damage are reported according to ELISA based on the manufacturer's instructions.
|
||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||
| Change History | No Changes Posted | ||||
| Current Secondary Outcome Measures ICMJE |
|
||||
| Original Secondary Outcome Measures ICMJE | Same as current | ||||
| Current Other Pre-specified Outcome Measures | Not Provided | ||||
| Original Other Pre-specified Outcome Measures | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | The Anti-oxidant Effects of N-Acetylcysteine in Chronic Obstructive Pulmonary Disease (COPD) | ||||
| Official Title ICMJE | The Effects of N-Acetylcysteine on Oxidative Stress Markers in Chronic Obstructive Pulmonary Disease (COPD) | ||||
| Brief Summary |
Chronic obstructive pulmonary disease (COPD) is a condition defined as a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of lungs to noxious particles or gases, primarily caused by cigarette smoking. The accelerated decline in lung function is closely associated with an increased number of neutrophils in the sputum and hence with higher level of airway inflammation. It becomes clear that the inflammatory process potentiates as COPD progresses and exerts damage which is irreversible. Oxidative stress is inextricably linked to the inflammatory response. There is increasing evidence that an oxidant/antioxidant imbalance, in favor of oxidants, occurs in COPD. NAC has been reported to reduce the viscosity of sputum in both cystic fibrosis and COPD, facilitating the removal of pulmonary secretions. Moreover, by maintaining the airway clearance, it prevents bacterial stimulation of mucin production and hence mucus hypersecretion. The superiority of NAC over the other mucolytics may be in its anti-inflammatory and antioxidant properties and its mucolytic actions. The aim of this study is to evaluate the effects of treatment with NAC long on oxidative stress marker change and also explore the effect of NAC to airway inflammatory, lung function test and CAT scores. Selected oxidative stress marker was defined as 8 - isoprostane, protein carbonyl, DNA damage. |
||||
| Detailed Description | Not Provided | ||||
| Study Type ICMJE | Interventional | ||||
| Study Phase ICMJE | Phase 3 | ||||
| Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Intervention Model Description: Pre-post study Masking: None (Open Label)Primary Purpose: Basic Science |
||||
| Condition ICMJE | Chronic Obstructive Pulmonary Disease | ||||
| Intervention ICMJE | Drug: N-acetylcysteine
All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
|
||||
| Study Arms ICMJE | Experimental: N-acetylcysteine treatment
All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
Intervention: Drug: N-acetylcysteine
|
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Unknown status | ||||
| Estimated Enrollment ICMJE |
30 | ||||
| Original Estimated Enrollment ICMJE | Same as current | ||||
| Estimated Study Completion Date ICMJE | May 1, 2020 | ||||
| Estimated Primary Completion Date | January 5, 2020 (Final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||
| Sex/Gender ICMJE |
|
||||
| Ages ICMJE | 40 Years to 90 Years (Adult, Older Adult) | ||||
| Accepts Healthy Volunteers ICMJE | No | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Listed Location Countries ICMJE | Thailand | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT03956888 | ||||
| Other Study ID Numbers ICMJE | TH_IIS_NAC_2018 | ||||
| Has Data Monitoring Committee | No | ||||
| U.S. FDA-regulated Product |
|
||||
| IPD Sharing Statement ICMJE |
|
||||
| Responsible Party | Kittipong Maneechotesuwan, Siriraj Hospital | ||||
| Study Sponsor ICMJE | Siriraj Hospital | ||||
| Collaborators ICMJE | Not Provided | ||||
| Investigators ICMJE |
|
||||
| PRS Account | Siriraj Hospital | ||||
| Verification Date | May 2019 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||
